A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC)
In this largest-to-date, first prospectively enrolled, real-world Chinese OC cohort, olaparib demonstrated a well-tolerated and manageable safety profile (including in special populations) with appropriate management, regardless of treatment lines. No new safety signals were identified.
Authors
- Weiwei Feng (ORCID: https://orcid.org/0000-0002-0685-9479)
- Zhen Shen (ORCID: https://orcid.org/0000-0002-6109-9775)
- Yingjie Yang (ORCID: https://orcid.org/0000-0001-8518-3018)
- Yuanming Shen (ORCID: https://orcid.org/0000-0002-0474-3472)
- Huaying Wang (ORCID: https://orcid.org/0000-0002-3780-4497)
- Wenjun Cheng (ORCID: https://orcid.org/0000-0003-3101-8476)
- Yue Wang
- Xipeng Wang (ORCID: https://orcid.org/0000-0002-7555-4185)
- Chunhua Tu
- Li Sun (ORCID: https://orcid.org/0000-0001-6141-562X)
- Qingshui Li
- Ziling Liu (ORCID: https://orcid.org/0000-0003-0582-7579)
- Lingling Xie (ORCID: https://orcid.org/0000-0002-8115-5068)
- Congzhu Li (ORCID: https://orcid.org/0000-0002-7761-1956)
- Qionghua Chen (ORCID: https://orcid.org/0000-0003-4637-9813)
- Rutie Yin (ORCID: https://orcid.org/0000-0002-9221-6727)
- Yi Zhang (ORCID: https://orcid.org/0000-0003-0351-5184)
- Xiping Luo (ORCID: https://orcid.org/0000-0002-0122-5880)
- Ge Lou
- Zhang Ping (ORCID: https://orcid.org/0000-0003-1995-9775)
- Jianwei Zhou (ORCID: https://orcid.org/0000-0002-7208-6179)
- Fengxia Xue (ORCID: https://orcid.org/0000-0001-9694-0061)
- Haiying Li (ORCID: https://orcid.org/0000-0002-8229-764X)
- Hongying Yang
- Hongwu Wen
- Shan Kang (ORCID: https://orcid.org/0000-0001-7790-2393)
- Dongyan Cao (ORCID: https://orcid.org/0000-0002-5699-8813)
- Zhongqiu Lin (ORCID: https://orcid.org/0000-0002-9891-2854)
- Bei Lin (ORCID: https://orcid.org/0000-0001-5347-4881)
- Ruixia Guo (ORCID: https://orcid.org/0000-0002-7718-0666)
- Yang Shen (ORCID: https://orcid.org/0000-0002-4326-8483)
- X. Wu (ORCID: https://orcid.org/0000-0001-7655-389X)
- Liguo Ma
- Li Wang (ORCID: https://orcid.org/0000-0002-0496-9500)
Institutions
- Hebei Medical University (CN)
- Nanchang University (CN)
- Guiyang Medical University (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Jilin University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Sichuan University (CN)
- Kunming Medical University (CN)
- Peking Union Medical College Hospital (CN)
- XinHua Hospital (CN)
- Ruijin Hospital (CN)
- Tianjin Medical University General Hospital (CN)
- Southern University of Science and Technology (CN)
- Shantou University (CN)
- Soochow University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- The Fourth People's Hospital (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Fudan University Shanghai Cancer Center (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Shandong Tumor Hospital (CN)
- Guizhou Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Zhongda Hospital Southeast University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Zhangjiagang First People's Hospital (CN)
- First Hospital of Jilin University (CN)
- Peking University First Hospital (CN)
- Henan Provincial People's Hospital (CN)
- Quantum Design (Germany) (DE)
- Women's Hospital, School of Medicine, Zhejiang University (CN)
- First Hospital of China Medical University (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Henan Cancer Hospital (CN)
- Guangdong Province Women and Children Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Shandong First Medical University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Shenzhen Second People's Hospital (CN)
- Nanjing Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1186/s13048-025-01924-8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00